key: cord-0849289-y309cvzo
authors: Kara, Emre; Demirkan, Kutay; Unal, Serhat
title: Recommendations for use of a hydroxychloroquine loading dose in patients with COVID-19
date: 2020-07-30
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106123
sha: 33af38dd013be404ced56a0d5b5befb7188f1355
doc_id: 849289
cord_uid: y309cvzo

nan

Sir, HCQ has a large volume of distribution (47.5 L) and a long elimination half-life (40-50 days). Overdose and toxicity risk may be higher especially in critically ill patients with impaired renal and/or hepatic function. Pharmacokinetic parameters of HCQ have been learned from studies in patients with rheumatic diseases and in healthy volunteers [1, 2] .

In an integrative modelling study by Garcia-Cremades et al., it was found that effective HCQ treatment either with a loading dose [800 mg twice a day (b.i.d.)

loading dose for 1-2 days followed by 400 mg b.i.d. maintenance dose] or without a loading dose (400 mg b.i.d. maintenance dose) for a 7-day regimen could be tolerated safely. Besides their safety, their effectiveness in terms of reducing the time of detectable viral load and improving treatment outcomes was also analysed. It was predicted that higher daily doses of HCQ (such as 800 mg b.i.d.) could result in an increased risk of QT prolongation [3] . (Table 1) .

Although these suggestions do not apply to all patients, clinicians need to consider the necessity of a loading dose for their patients individually. Clinicians should consider the effect of individual patient conditions (e.g. obesity, sepsis, burn, ascites, pregnancy, critical illness) and changes in pharmacokinetic (e.g. increased drug volume of distribution) and pharmacodynamic (e.g. decreased effectiveness, increased adverse effects) parameters on HCQ prescribing. We believe that randomised controlled studies should be conducted to evaluate HCQ use with and without a loading dose in terms of effectiveness and safety.

Funding: None. 

Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis

Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC-MS/MS

Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing

Finding the dose for hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness

In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus

Ethical approval: Not required.